For decades, pancreatic cancer has occupied a grim corner of medicine where silence precedes catastrophe and treatment offers little more than borrowed time. Now, a drug called daraxonrasib has done what scientists long believed impossible — reached into the molecular machinery of the disease and interrupted the signal that drives it, nearly doubling survival time for patients with metastatic pancreatic cancer. The breakthrough, born from a phase 3 trial released in May 2026, does not promise a cure, but it marks the first meaningful breach in a wall that has held for generations.
Daraxonrasib doubles pancreatic cancer survival, targeting previously 'undruggable' KRAS mutation
Pancreatic cancer patients with metastatic disease face severe mortality, with 97% of those diagnosed between 2015-2021 dying within five years; this treatment offers extended survival and improved quality of life.
The switch locked permanently in the 'on' position, commanding cells to multiply without restraint.
Mark
Why did KRAS stay untreatable for so long? It seems like something scientists would have solved decades ago.
Mimi
The protein's surface is smooth—almost featureless. Drugs work by fitting into pockets or grooves on a protein's surface, like a key in a lock. KRAS has no lock. It's just a flat wall. For years, that flatness meant no drug could grip it.
Mark
So daraxonrasib doesn't actually touch KRAS directly?
Mimi
No. It uses a middleman. It binds to cyclophilin A, a protein already inside the cell doing its own job. Once daraxonrasib is attached to cyclophilin A, that complex can finally grab hold of KRAS and disable it.
Mark
That sounds like a workaround. Why is that better than just finding a way to hit KRAS head-on?
Mimi
Because sometimes the direct path doesn't exist. The indirect path was the only path available. And it works.
Mark
The survival numbers—6.7 months to 13.2 months. That's still very short. Does this drug feel like a real victory?
Mimi
It depends on what you're measuring. It's not a cure. But for a disease where 97 percent of patients were dead in five years, where chemotherapy was the only option and it barely slowed the disease, doubling survival time and reducing suffering is a genuine shift. It's not the end of the story. It's the beginning of one.
Mark
What happens to patients now?
Mimi
They wait for FDA approval. If it comes, daraxonrasib becomes available to people with metastatic pancreatic cancer who've already tried chemotherapy. It won't save everyone. But it will give more people more time.
O Pulso
- Pancreatic cancer kills with near-total efficiency — 97% of metastatic patients diagnosed between 2015 and 2021 were dead within five years, and chemotherapy remained the only real option despite its brutal limitations.
- The KRAS gene mutation, present in over 90% of pancreatic tumors, had resisted every drug ever aimed at it, earning the label 'undruggable' and leaving researchers at a molecular dead end for decades.
- Daraxonrasib circumvents the problem entirely by binding to a helper protein called cyclophilin A, which then enables the drug to latch onto and silence the mutated KRAS — a precision workaround where direct assault had always failed.
- In a 500-patient phase 3 trial, median survival jumped from 6.7 to 13.2 months, mortality risk dropped 60% versus chemotherapy, and patients reported meaningfully less pain and better quality of life despite common side effects.
- Revolution Medicines is now pursuing FDA approval, positioning daraxonrasib as a potential new standard of care for a disease that has historically offered patients almost nothing beyond palliation.
For decades, pancreatic cancer has occupied a grim corner of medicine where silence precedes catastrophe and treatment offers little more than borrowed time. Now, a drug called daraxonrasib has done what scientists long believed impossible — reached into the molecular machinery of the disease and interrupted the signal that drives it, nearly doubling survival time for patients with metastatic pancreatic cancer. The breakthrough, born from a phase 3 trial released in May 2026, does not promise a cure, but it marks the first meaningful breach in a wall that has held for generations.
Pancreatic cancer has long functioned as a quiet executioner. It spreads without warning — jaundice or abdominal pain often arrive only after the tumor has already reached other organs — and the five-year survival rate for metastatic cases hovers near three percent. Chemotherapy, the only widely available treatment, attacks fast-dividing cells indiscriminately and loses effectiveness as cancer cells develop resistance. For patients, a diagnosis has meant not a fight but a countdown.
On May 31, 2026, Revolution Medicines announced phase 3 trial results for daraxonrasib, an oral drug that has nearly doubled survival time in advanced pancreatic cancer. Median survival extended from 6.7 to 13.2 months — a 60 percent reduction in mortality risk compared to standard chemotherapy. The result is the most significant advance against this disease in memory.
The science behind it required rethinking what 'treatment' could even mean. More than 90 percent of pancreatic tumors carry a KRAS gene mutation that locks cell growth permanently into overdrive. The KRAS protein's unusually smooth surface offered no foothold for conventional drugs, and it was long considered untreatable. Daraxonrasib takes an indirect path: it binds to a separate protein called cyclophilin A, which then enables it to grip and silence the mutated KRAS — a workaround that reaches what direct approaches never could.
The trial enrolled 500 patients who had already undergone chemotherapy. Side effects were common — rash appeared in over 86 percent of participants, alongside mouth sores, nausea, and diarrhea — but patients were far less likely to stop treatment due to severe toxicity than those on chemotherapy. They reported less pain and better quality of life. The drug is taken as a pill, not an infusion, a detail that carries real weight for people already weakened by disease.
Thirteen months is still a short life. But it is nearly twice what patients had before, and it is lived with less suffering. With FDA approval now being pursued, daraxonrasib stands at the edge of becoming a new standard of care — not a cure, but a threshold crossed in a disease that has, until now, crossed nearly everyone.
Pancreatic cancer has long been a death sentence. Among patients diagnosed with the metastatic form between 2015 and 2021, roughly 97 percent were dead within five years. The disease offers almost no warning—it spreads silently until jaundice or abdominal pain arrives, by which point the tumor has already colonized other organs. Doctors have had little to offer beyond chemotherapy, a blunt instrument that poisons fast-dividing cells indiscriminately, destroying healthy tissue alongside the malignant, and to which cancer cells develop resistance with alarming speed.
But something has shifted. On May 31, 2026, the biotech company Revolution Medicines released the results of a phase 3 clinical trial for a drug called daraxonrasib, an oral medication that has nearly doubled survival time in patients with advanced pancreatic cancer. The median survival extended from 6.7 months to 13.2 months—a 60 percent reduction in mortality risk compared to standard chemotherapy. For a disease that has resisted effective treatment for decades, the result amounts to a fundamental breach in an otherwise impenetrable wall.
The breakthrough hinges on understanding what makes pancreatic cancer so lethal in the first place. More than 90 percent of pancreatic tumors carry a mutation in the KRAS gene, which normally acts as a molecular switch controlling cell growth. When KRAS mutates, that switch locks permanently in the "on" position, commanding cancer cells to multiply without restraint. For years, scientists considered KRAS untreatable. The protein's surface is unusually smooth, lacking the molecular pockets where conventional drugs could grip and disable it. The gene seemed, in technical terms, undruggable.
Daraxonrasib solves this problem through an indirect route. Rather than attacking KRAS directly, the drug binds to a protein called cyclophilin A inside the cell—a molecule normally responsible for helping other proteins fold into their proper three-dimensional shapes. Once bound to cyclophilin A, daraxonrasib becomes capable of latching firmly onto the mutated KRAS protein and shutting down its ability to send growth signals. It is a workaround born of precision, a way of reaching something that seemed unreachable.
The trial enrolled 500 patients with metastatic pancreatic cancer who had already undergone chemotherapy. The results were unambiguous. Daraxonrasib extended life, but it also changed the texture of that life. While side effects were common—a rash affected more than 86 percent of participants, and mouth sores, diarrhea, nausea, and vomiting appeared regularly—patients on daraxonrasib were far less likely to abandon treatment due to severe toxicity. They reported better quality of life and significantly less pain than those receiving chemotherapy. The drug is a pill taken by mouth, not an infusion, which itself matters for patients already weakened by disease.
What happens next is procedural but consequential. Revolution Medicines will seek FDA approval, a step that could position daraxonrasib as a new standard of care for a disease that has long offered patients almost no hope. The drug will not cure pancreatic cancer. Thirteen months is still a short life. But it is nearly twice as long as before, and it is a life lived with less suffering. For a disease that has killed nearly everyone it touches, that represents a threshold crossed.
Citações Notáveis
The drug binds to cyclophilin A inside the cell, allowing it to grip the mutated KRAS protein and shut down its growth signals— Trial mechanism of action
Quer a matéria completa?
Leia o original em ADN Radio ↗
Health & Medicine